Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ostin Technology Group Co., Ltd. designs, develops, and manufactures thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers in China. The company offers TFT-LCD solutions for drive IC, TCON board, and power supply applications; back light systems and special modules; LC display modules, touch panel modules, and smart display terminals; and polarizers used in the TFT-LCD display modules. It offers display modules to markets, such as consumer electronics, including AIOs, monitors, laptop computers, and tablets; automotive displays, including dashboard, and navigation and multimedia systems; and outdoor LCD displays, which are used to display multimedia graphics, such as company advertisements, promotions, scoreboards, and traffic signs. The company sells its products directly to customers, as well as to customers' designated system integrators. Ostin Technology Group Co., Ltd. was founded in 2010 and is based in Nanjing, China with manufacturing facilities in China.

Ostin Technology Group Co., Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 22, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED ADDITIONAL OVERALL AND EVENT FREE SURVIVAL DATA GENERATED FROM THE COMPANY'S 41-PATIENT PHASE 2B CLINICAL TRIAL OF ITS OFF-THE-SHELF IMMUNOTHERAPEUTIC CANDIDATE OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE "PHASE 2B OSTEOSARCOMA TRIAL"). THE COMPANY PREVIOUSLY ANNOUNCED STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM ITS PHASE 2B OSTEOSARCOMA TRIAL ON OCTOBER 10, 2025.

OS THERAPIES ANNOUNCES OVERALL AND EVENT FREE SURVIVAL KEY SUBGROUP DATA FOR OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

75% OF OST-HER2 TREATED PATIENTS ACHIEVED 2-YEAR OVERALL SURVIVAL COMPARED WITH 40% IN THE HISTORICAL CONTROL GROUP (P < 0.0001) 100% OF PATIENTS WHO ACHIEVED 12 MONTH EVENT FREE SURVIVAL ACHIEVED 2 YEAR OVERALL SURVIVAL NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 10, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM THE COMPANY'S PHASE 2B TRIAL OF OFF-THE-SHELF IMMUNOTHERAPY CANDIDATE OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE "FULLY RESECTED METASTATIC OSTEOSARCOMA TRIAL"). 75% (27 OUT OF 36 EVALUABLE PATIENTS; 5 PATIENTS WERE LOST TO FOLLOW-UP) OF OST-HER2 TREATED PATIENTS ACHIEVED 2-YEAR OVERALL SURVIVAL AS MEASURED FROM MOST RECENT PULMONARY RESECTION, COMPARED WITH 40% OF HISTORICAL CONTROL PATIENTS1 (P < 0.0001) SUBGROUP ANALYSES SHOWED THAT 100% OF PATIENTS WHO ACHIEVED 12-MONTH EVENT FREE SURVIVAL (EFS) ACHIEVED 2-YEAR OVERALL SURVIVAL, WHEREAS 59% OF PATIENTS WHO DID NOT ACHIEVE EFS ACHIEVED 2-YEAR OVERALL SURVIVAL.

OS THERAPIES ANNOUNCES STATISTICALLY SIGNIFICANT POSITIVE FINAL 2-YEAR OVERALL SURVIVAL DATA FROM PHASE 2B TRIAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

COMPANY UPDATES SEQUENCE OF OST-HER2 REGULATORY SUBMISSIONS, PRIORITIZING UK MHRA CONDITIONAL MARKETING AUTHORISATION APPLICATION (MAA) SUBMISSION FOLLOWING POSITIVE AUGUST 2025 SCIENTIFIC ADVICE MEETING FEEDBACK FROM UK MHRA IN PRINCIPLE, UK MHRA ACCEPTS USE OF HISTORICAL CONTROL ARM TO SUPPORT CONDITIONAL MAA UK MHRA CONDITIONAL MAA AND US FDA BIOLOGICS LICENSING APPLICATION (BLA) SUBMISSIONS EXPECTED TO BE COMPLETED WITHIN 30 DAYS OF EACH OTHER, BETWEEN DECEMBER 2025 AND JANUARY 2026 COMPANY TO PROPOSE USE OF IMMUNE ACTIVATION BIOMARKER COUPLED WITH OVERALL SURVIVAL DATA AS SURROGATE EFFICACY ENDPOINT TO SUPPORT ACCELERATED APPROVAL IN TYPE C MEETING INVITED BY FDA, FOLLOWING POSITIVE END OF PHASE 2 MEETING AND FOLLOW-UP INTERACTIONS NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY PROVIDED A REGULATORY UPDATE ON ITS PLANS FOR FILING MARKETING AUTHORIZATIONS IN THE UNITED STATES (US) AND UNITED KINGDOM (UK) FOR OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA BASED ON A DATA GENERATED FROM ITS COMPLETED PHASE 2B CLINICAL TRIAL CURRENTLY IN THE LONG TERM FOLLOW-UP PHASE. THE COMPANY HAS UPDATED ITS REGULATORY FILING SEQUENCE TO PRIORITIZE THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) CONDITIONAL MARKETING AUTHORISATION APPLICATION (MAA) FINAL MODULE SUBMISSION TO IMMEDIATELY PRECEDE ITS US FDA BIOLOGICS LICENSING APPLICATION (BLA) FINAL MODULE SUBMISSION UNDER THE ACCELERATED APPROVAL PROGRAM (ACCELERATED APPROVAL).

OS THERAPIES PROVIDES OST-HER2 UK MHRA AND US FDA OSTEOSARCOMA REGULATORY UPDATE

CLINICAL DATA FROM PHASE 1B PROSTATE CANCER TRIAL TO BE RELEASED IN Q4/25 ADDITIONALLY, UPDATED 2-YEAR OVERALL SURVIVAL DATA FROM ALL 40 PATIENTS IN THE PHASE 2B CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OF DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA TO BE RELEASED ON OCTOBER 10, 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 12, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED THAT THE LAST PATIENT ENROLLED IN ITS OST-504 (PREVIOUSLY ADXS-504) PHASE 1B CLINICAL TRIAL IN SUBJECTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER PREVIOUSLY TREATED WITH RADICAL PROSTATECTOMY (RP) OR RADIATION THERAPY (EXTERNAL BEAM OR BRACHYTHERAPY) WHO ARE NOT CURRENTLY RECEIVING ANDROGEN ABLATION THERAPY HAS COMPLETED THEIR LAST PATIENT VISIT (NCT05077098). A TOTAL OF 7 PATIENTS ENROLLED IN THE STUDY.

OS THERAPIES ANNOUNCES LAST PATIENT ENROLLED IN OST-504 (PREVIOUSLY ADXS-504) PHASE 1B PROSTATE CANCER CLINICAL TRIAL COMPLETES LAST VISIT

COMPANY ON TRACK TO BEGIN SUBMISSION OF A ROLLING BIOLOGICS LICENSING APPLICATION (BLA) REQUEST FOR OST-HER2 TO U.S. FOOD & DRUG ADMINISTRATION IN SEPTEMBER 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 2, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY PROVIDED STAKEHOLDERS WITH A DETAILED UPDATE REGARDING THE COMPANY'S OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA PROGRAM (THE "METASTATIC OSTEOSARCOMA PROGRAM") FOLLOWING A HIGHLY PRODUCTIVE END OF PHASE 2 MEETING WITH THE US FOOD & DRUG ADMINISTRATION ("FDA"). THE COMPANY REMAINS ON TRACK TO BEGIN ROLLING SUBMISSION OF A BIOLOGICS LICENSING APPLICATION ("BLA") REQUEST TO FDA FOR THE METASTATIC OSTEOSARCOMA PROGRAM IN SEPTEMBER 2025.

OS THERAPIES PROVIDES OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA PROGRAM UPDATE FOLLOWING FDA END OF PHASE 2 MEETING

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 27, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY ANNOUNCED THAT IT WILL PROVIDE STAKEHOLDERS WITH A DETAILED UPDATE REGARDING THE COMPANY'S HIGHLY CONSTRUCTIVE AUGUST 27, 2025 END OF PHASE 2 MEETING WITH THE US FOOD & DRUG ADMINISTRATION ("FDA") DISCUSSING THE REGULATORY PATH FORWARD TOWARDS APPROVAL FOR OST-HER2 IN RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA ON TUESDAY, SEPTEMBER 2, 2025. ABOUT OS THERAPIES OS THERAPIES IS A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON THE IDENTIFICATION, DEVELOPMENT, AND COMMERCIALIZATION OF TREATMENTS FOR OSTEOSARCOMA (OS) AND OTHER SOLID TUMORS.

OS THERAPIES TO PROVIDE OST-HER2 RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA FDA END OF PHASE 2 MEETING UPDATE ON TUESDAY, SEPTEMBER 2, 2025

U.S. FDA ("FDA") CONFIRMS OST-HER2 MEETS BIOLOGICAL DEFINITION OF REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) FDA ISSUES OST-HER2 BLA NUMBER IN PREPARATION FOR ACCELERATED APPROVAL SUBMISSION FOLLOWING END OF PHASE 2 MEETING FDA END OF PHASE 2 MEETING SCHEDULED FOR AUGUST 27, 2025 TO REVIEW PHASE 2B CLINICAL TRIAL IN THE PREVENTION OR DELAY OF RECURRENT, PULMONARY METASTATIC OSTEOSARCOMA STATISTICALLY SIGNIFICANT 12-MONTH EVENT FREE SURVIVAL AND INTERIM 2-YEAR OVERALL SURVIVAL AND STRONG SAFETY DATA IN PHASE 2B TRIAL DRIVES GLOBAL ACCELERATED/CONDITIONAL APPROVAL PATHWAYS COMMERCIAL PARTNERSHIP WITH EVERSANA POSITIONS OST-HER2 FOR POSSIBLE U.S. LAUNCH IN FIRST HALF OF 2026 $4.2 MILLION CAPITAL RAISE, CLOSED JULY 11, 2025 VIA WARRANT EXERCISE INDUCEMENT AND EXCHANGE OFFERING, EXTENDS CASH RUNWAY INTO MID-2026 NYSE AMERICAN-LISTED OSTX INCLUDED IN THE RUSSELL MICROCAP, RUSSELL MICROCAP VALUE AND RUSSELL MICROCAP GROWTH INDEXES NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 19, 2025) - OS THERAPIES INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE CANCER IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE BIOTECHNOLOGY COMPANY, TODAY REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE. "THE COMPANY GAINED SIGNIFICANT MOMENTUM IN THE SECOND QUARTER AS WE BEGAN TO MAKE MEANINGFUL CLINICAL AND REGULATORY PROGRESS ON OUR PATH TOWARDS BRINGING THE FIRST NEW TREATMENT FOR OSTEOSARCOMA TO MARKET IN THE UNITED STATES IN THE LAST 40 YEARS," SAID PAUL ROMNESS, MPH, CHAIRMAN & CEO OF OS THERAPIES.

OS THERAPIES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MHRA SEEKS TO HARMONIZE UK & US REGULATORY REVIEW VIA PROJECT ORBIS EMA RAPPORTEUR SCIENTIFIC ADVICE MEETING SCHEDULED FOR OCTOBER 2025 NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 7, 2025) - OS THERAPIES (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), A CLINICAL-STAGE IMMUNOTHERAPY AND ANTIBODY DRUG CONJUGATE (ADC) BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT HELD A SUCCESSFUL SCIENTIFIC ADVICE MEETING WITH THE UNITED KINGDOM'S (UK) MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) IN JULY AND HAS SUBMITTED AN INVITED INNOVATIVE LICENSING AND ACCESS PATHWAY (ILAP) APPLICATION TO BEGIN THE REGULATORY PROCESS TOWARDS APPROVAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA. MHRA SUGGESTED APPLYING FOR PROJECT ORBIS AT THE TIME OF REGULATORY APPROVAL SUBMISSION TO SYNCHRONIZE ITS MARKETING AUTHORIZATION APPLICATION PROCESS WITH THE UNITED STATES FOOD & DRUG ADMINISTRATION'S (FDA) BIOLOGICS LICENSING APPLICATION (BLA) ACCELERATED APPROVAL PROGRAM.

OS THERAPIES RECEIVES POSITIVE FEEDBACK FROM UK MHRA SCIENTIFIC ADVICE MEETING AND SUBMITS INNOVATIVE LICENSING AND ACCESS PATHWAY (ILAP) REQUEST FOR OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

NANJING, CHINA, JULY 28, 2025 (GLOBE NEWSWIRE) -- OSTIN TECHNOLOGY GROUP CO., LTD. ("THE COMPANY") (NASDAQ:OST), A LEADING SUPPLIER OF DISPLAY MODULES AND POLARIZERS BASED IN CHINA, TODAY ANNOUNCED THAT IT HAS RESOLVED TO EFFECT A REVERSE SHARE SPLIT OF THE COMPANY'S ORDINARY SHARES, WITH THE SPLIT RATIO SET AT 1-FOR-25 (THE "THE REVERSE SHARE SPLIT"). THE REVERSE SHARE SPLIT WAS APPROVED BY THE COMPANY'S SHAREHOLDERS AT AN EXTRAORDINARY GENERAL MEETING HELD ON JULY 17, 2025. THE COMPANY'S CLASS A ORDINARY SHARES WILL BEGIN TRADING ON AN ADJUSTED BASIS, REFLECTING THE REVERSE SHARE SPLIT, ON AUGUST 5, 2025, UNDER THE EXISTING TICKER SYMBOL "OST." THE NEW CUSIP NUMBER FOR THE COMPANY'S CLASS A ORDINARY SHARES WILL BE G67927122.

OSTIN TECHNOLOGY GROUP CO., LTD. ANNOUNCES 1-FOR-25 REVERSE SHARE SPLIT EFFECTIVE AUGUST 5, 2025

NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- UNIVEST SECURITIES, LLC (UNIVEST), A MEMBER OF FINRA AND SIPC, AND A FULL-SERVICE INVESTMENT BANK AND SECURITIES BROKER-DEALER FIRM BASED IN NEW YORK, TODAY ANNOUNCED THE CLOSING OF REGISTERED DIRECT OFFERING (THE OFFERING), FOR ITS CLIENT OSTIN TECHNOLOGY GROUP CO., LTD. (NASDAQ: OST) (THE COMPANY), A LEADING SUPPLIER OF DISPLAY MODULES AND POLARIZERS BASED IN CHINA.

Ostin Technology Group Co., Ltd.

OST

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ostin Technology Group Co., Ltd.

OST.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OST